WAT Waters Corporation

Waters New ACQUITY Arc Bio System Brings Advanced Method Transfer Capabilities to Routine Bioseparations

Waters Corporation (NYSE:WAT) today introduced the Waters® ACQUITY Arc™ Bio System, a versatile, iron-free, bio-inert, quaternary liquid chromatograph specifically engineered to enable the efficient transfer and improvement of bioseparation analytical methods regardless of the LC platform on which the original method was developed.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180130005282/en/

The Waters ACQUITY Arc Bio System is an iron-free, bio-inert, quaternary liquid chromatograph specif ...

The Waters ACQUITY Arc Bio System is an iron-free, bio-inert, quaternary liquid chromatograph specifically engineered to enable the efficient transfer and improvement of bioseparation analytical methods regardless of the LC platform on which the original method was developed. (Photo: Business Wire)

Since its 2015 launch, the original ACQUITY Arc System has become a workhorse of pharmaceutical development and QC laboratories throughout the world. With the introduction of the ACQUITY Arc Bio System, biopharmaceutical laboratories can take advantage of the power of the ACQUITY Arc™ platform for creating robust and reliable methods that can be transferred easily from lab-to-lab and from one LC instrument platform to another without compromising method integrity.

“For many GLP/GMP laboratories, developing and transferring validated assays for routine product release and multi-attribute monitoring is a fundamental task which Waters is committed to simplifying with the Arc Bio System,” said Dr. Diane Diehl, Senior Director, Pharmaceutical Market Development. “With today’s introduction, and yesterday’s launch of the BioResolve RP mAb Columns, Waters is continuing its commitment to the biopharmaceutical industry by meeting the needs of analytical scientists and lab managers across the discovery, development and manufacturing pipeline.”

The ACQUITY Arc Bio System is ideally suited to run reversed-phase, ion exchange, size exclusion and hydrophobic interaction LC methods with minimal carryover and maximum recovery of biomolecules. The ACQUITY Arc Bio System’s flow paths are made of non-stainless steel and iron-free bio-inert materials designed to minimize undesirable protein interactions and maximize system robustness under salt and pH extremes. What also sets the instrument apart is the unique Arc Multi-flow path™ technology which delivers plug-and-play compatibility with HPLC or UHPLC methods through a selectable dwell volume, emulating the dwell volume of the original instrument. This minimizes the time it takes laboratories to redevelop methods from internal and external partners.

In addition to replicating established HPLC assays, the ACQUITY Arc Bio System can improve the sensitivity, resolution and speed of chromatography methods by leveraging more modern, more efficient 2.5 - 2.7 micron particle column technologies. These include the new Waters BioResolve™ RP mAb Polyphenyl solid core Columns for the reproducible analysis of intact or sub units of monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs). The system also supports previously developed “legacy” methods on traditional 3 - 5 micron HPLC columns.

The ACQUITY Arc Bio System is compatible with numerous detectors from Waters, including photodiode array, UV/Vis, fluorescence, refractive index, evaporative light scattering and the ACQUITY QDa™ mass detector. In addition, the ACQUITY Arc Bio System features novel Auto Blend Plus™ Technology that automatically blends up to four solvents in any combination or proportion and allows the operator to program in pH and ionic strength for ion-exchange or size exclusion-based methods, or program in the organic solvent concentration and pH for reversed-phase gradient separations. This significantly reduces human error and the task of preparing buffered mobile phases manually. The ACQUITY Arc Bio System is controlled through Waters Empower 3 and MassLynx software.

The ACQUITY Arc Bio System is immediately available for purchase worldwide.

For more information on Waters ACQUITY Arc Bio System: www.waters.com/arcbio

About Waters Corporation (www.waters.com)

Waters Corporation (NYSE: WAT), the world's leading specialty measurement company, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, and food sciences for nearly 60 years. With approximately 7,000 employees worldwide, Waters operates directly in 31 countries, including 15 manufacturing facilities, and with products available in more than 100 countries.

Waters, ACQUITY, ACQUITY Arc, Arc, Arc Multi-flow path, ACQUITY QDa, Auto Blend Plus, Empower, MassLynx, BioResolve and UPLC are trademarks of Waters Corporation.

EN
30/01/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Waters Corporation

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Back to Near-Term Bullish on SPX and QQQ We downgraded our near-term outlook on the S&P 500 (SPX) and Nasdaq 100 (QQQ) to neutral last week (11/19/25 Compass), after being bullish since our 4/22/25 Compass, while maintaining our intermediate-term bullish outlook (as of our 5/14/25 Compass). Crucial support levels of 6480-6520 on SPX and $580-$583 on QQQ held last week, and we are right back to being near-term bullish as long as these support levels continue to hold. Just know that SPX could see...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

6550-6569 S&P 500 Support Holding For Now After 5.5-months, the S&P 500 (SPX) has now failed to break and stay below the its 20-day MA. However, 6569 has been our level that needs to break in order for us to have confidence that a pullback has begun; SPX made a low of 6551 on Friday (less than 20 points or 0.3% from our 6569 level), meaning it was not a decisive breakdown (in time or price). As a result, our near-term bullish outlook since our 4/22/25 Compass remains intact, and it will stay t...

Waters Corp: 1 director

A director at Waters Corp bought 1,000 shares at 332.900USD and the significance rating of the trade was 87/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch